摘要
目的:研究糖肝康对糖尿病脂肪肝模型大鼠肝脏组织中过氧化物酶增殖物活化受体γ辅激活因子1α(PGC-1α)、过氧化物增殖物活化受体α(PPARα)表达的影响。方法:选取70只SPF级雄性Wistar大鼠,用高糖高脂饮食+链脲佐菌素(STZ)腹腔注射建立糖尿病脂肪肝大鼠模型,并分为5组(n=10):模型组,糖肝康小、中、大剂量组及护肝宁组,另选10只大鼠设为正常组,分别灌胃。药物干预12周后,采用荧光PCR方法检测肝脏组织中PGC-1αm RNA表达、western blot方法检测肝脏组织中PPARα的表达。结果:造模后大鼠的肝脏组织中PGC-1α表达升高,PPARα表达降低,糖肝康对模型大鼠肝脏组织PGC-1α的异常表达有抑制作用,对PPARα有促进作用。结论:糖尿病脂肪肝的发生发展可能与PPARα的异常表达相关,糖肝康可通过抑制PGC-1α、升高PPARα表达水平,调节糖脂代谢紊乱和胰岛素敏感性。
Objective： To observe the effects of Tanggankang on the expressions of PGC-1α, PPARα in the liver of diabetic-fatty liver rats model. Methods： Seventy SPF grade Wistar rats were selected to establish the diabetic-fatty liver model with STZ by intraperitioneal injection and high-quality and high-carbohydrate diet, and departed into five groups（n=10）： model control group, Huganning group, Tanggankang low-dose, medium-dose and high-dose groups, while blank control group composed with 10 normal rats. After 12 weeks of drug intervention, the m RNA expressions of PGC-1α in the liver was observed by the method of real-time fluorescent PCR. The expressions of PPARα in the liver was observed by the method of western blot. Results： The m RNA expression of PGC-1α in the liver was significantly increased and the expression of PPARα in the liver was significantly reduced, Tanggankang could lower the expression of PGC-1α and increase the expression of PPARα. Conclusion： The abnormal expression of PPARα could be one of the mechanisms for diabetic-fatty liver. Tanggankang has a good protective effect on regulating glucose and lipid metabolism disorder and insulin sensitivity by inhibiting the expression of PGC-1α and PPARα.
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2015年第7期2525-2528,共4页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
山东省自然科学基金委面上项目(No.ZR2012HM093)
山东省中医药科技发展计划项目(No.2011-038)~~
